(Q40998745)

25 September 2017

1 reference

title

Combined androgen blockade for the treatment of metastatic cancer of the prostate (English)

1 reference

25 September 2017

Schellhammer PF

1

1 reference

PubMed ID

8650856

25 September 2017

language of work or name

English

0 references

publication date

1 May 1996

1 reference

25 September 2017

1 reference

25 September 2017

47

1 reference

25 September 2017

5

1 reference

25 September 2017

622-628

1 reference

Cancer in the European community and its member states

25 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Carcinoma of the Prostate in Elderly Men: Incidence, Growth Characteristics and Clinical Significance

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Combination treatment in M1 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Risk factors for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Some statistical considerations for the interpretation of trials of combined androgen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Leuprolide with and without flutamide in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Complete androgen blockade in prostate cancer. Organizing an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Systematic overview (metaanalysis) of all randomized trials of treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Comparability of EORTC and DAPROCA studies in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Comparability of prostate trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

Overview analysis issues using combined androgen deprivation overview analysis as an example.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900002-7

7 January 2021

10.1016/S0090-4295(96)00002-7

Identifiers

DOI

1 reference

25 September 2017

1 reference

PubMed ID

8650856